We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 17, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include TOTAL S.A. , Humana (HUM - Free Report) , Novo Nordisk (NVO - Free Report) , Target (TGT - Free Report) and Xcel (XEL - Free Report) .
Top Analyst Reports for TOTAL, Humana and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including TOTAL S.A., Humana and Novo Nordisk. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of TOTAL S.A. have gained +7.3% year to date, outperforming the Zacks Integrated International Oil industry which has increased +2.5% over the same period. The company’s third- quarter earnings topped expectations on solid operational performance, steadily decreasing breakeven production costs, improvement in the realized prices of commodities and new project ramp ups.
The Zacks analyst likes TOTAL’s new start-ups and acquisitions, which are helping it to boost production. Its decision to acquire Maersk Oil for $7.45 billion will further strengthen its position globally as an oil and gas operator.
Going forward, the company will continue to benefit from its cost management initiatives. However, fluctuating commodity prices, operations in some politically troubled regions and increasing competition could impact the company’s profitability. Due to its global presence, it is also exposed to risks associated with doing business abroad.
Shares of Humana have underperformed the Zacks Health Maintenance Organization industry over the last one year, gaining +15.4% vs. 38.8%. Humana’s third-quarter 2017 earnings not only beat expectations but improved year over year driven by lower share count.
The Zacks analyst likes Humana’s strong government business. Its top line has been witnessing an uptrend for past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value.
Humana’s sound balance sheet and disciplined capital management remains a positive. Its strong fundamentals are likely to help the stock gain momentum going forward. However, the company's individual commercial business has remained a drag over past few years.
Novo Nordisk's shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date (up +38.5% vs. +14.1%). Novo Nordisk’s earnings in third-quarter 2017 topped expectations but revenues missed the same. The Zacks analyst likes the company’s strong pipeline which mainly focuses on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone.
The company's Diabetes segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. However, continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy will be partly offset by the impact of lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy, intensifying competition within the diabetes and biopharmaceutics markets and macroeconomic conditions in many markets under International Operations.
Other noteworthy reports we are featuring today include Target and Xcel.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
For Immediate Release
Chicago, IL – November 17, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include TOTAL S.A. , Humana (HUM - Free Report) , Novo Nordisk (NVO - Free Report) , Target (TGT - Free Report) and Xcel (XEL - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for TOTAL, Humana and Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including TOTAL S.A., Humana and Novo Nordisk. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of TOTAL S.A. have gained +7.3% year to date, outperforming the Zacks Integrated International Oil industry which has increased +2.5% over the same period. The company’s third- quarter earnings topped expectations on solid operational performance, steadily decreasing breakeven production costs, improvement in the realized prices of commodities and new project ramp ups.
The Zacks analyst likes TOTAL’s new start-ups and acquisitions, which are helping it to boost production. Its decision to acquire Maersk Oil for $7.45 billion will further strengthen its position globally as an oil and gas operator.
Going forward, the company will continue to benefit from its cost management initiatives. However, fluctuating commodity prices, operations in some politically troubled regions and increasing competition could impact the company’s profitability. Due to its global presence, it is also exposed to risks associated with doing business abroad.
(You can read the full research report on TOTAL S.A here >>>).
Shares of Humana have underperformed the Zacks Health Maintenance Organization industry over the last one year, gaining +15.4% vs. 38.8%. Humana’s third-quarter 2017 earnings not only beat expectations but improved year over year driven by lower share count.
The Zacks analyst likes Humana’s strong government business. Its top line has been witnessing an uptrend for past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value.
Humana’s sound balance sheet and disciplined capital management remains a positive. Its strong fundamentals are likely to help the stock gain momentum going forward. However, the company's individual commercial business has remained a drag over past few years.
(You can read the full research report on Humana here >>>).
Novo Nordisk's shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date (up +38.5% vs. +14.1%). Novo Nordisk’s earnings in third-quarter 2017 topped expectations but revenues missed the same. The Zacks analyst likes the company’s strong pipeline which mainly focuses on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone.
The company's Diabetes segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. However, continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy will be partly offset by the impact of lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy, intensifying competition within the diabetes and biopharmaceutics markets and macroeconomic conditions in many markets under International Operations.
(You can read the full research report on Novo Nordisk here >>>).
Other noteworthy reports we are featuring today include Target and Xcel.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.